3.
Stage distribution of diagnosed colorectal cancers during the 10–12 year follow-up of the NORCCAP trial compared to MISCAN-Colon predictions
| NORCCAP trial* | MISCAN-Colon | ||||
|---|---|---|---|---|---|
| Control Group | No. | (%) | No. | (%) | P value |
| Localized CRC | 470 | (45.5%) | 489 | (47.3%) | |
| Advanced CRC | 562 | (54.5%) | 545 | (52.7%) | 0.45 |
| Intervention group | |||||
| Localized CRC | 117 | (49.4%) | 155 | (52.6%) | |
| Advanced CRC | 120 | (50.6%) | 139 | (47.4%) | 0.50 |
Abbreviations: CRC, colorectal cancer; NORCCAP, Norwegian Colorectal Cancer Prevention Trial; MISCAN, Microsimulation Screening Analysis
*
Unclassified cancers in the control group (N=16) and in the intervention group (N=4) were excluded from this table.